These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29549468)

  • 1. A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study.
    Lanzillo R; Prosperini L; Gasperini C; Moccia M; Fantozzi R; Tortorella C; Nociti V; Annovazzi P; Cavalla P; Radaelli M; Malucchi S; Clerici VT; Boffa L; Buttari F; Ragonese P; Maniscalco GT; Di Filippo M; Buscarinu MC; Pinardi F; Gallo A; Coghe G; Pesci I; Laroni A; Gajofatto A; Calabrese M; Tomassini V; Cocco E; Solaro C;
    J Neurol; 2018 May; 265(5):1174-1183. PubMed ID: 29549468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register.
    D'Amico E; Zanghì A; Romeo M; Cocco E; Maniscalco GT; Brescia Morra V; Paolicelli D; De Luca G; Galgani S; Amato MP; Salemi G; Inglese M; Confalonieri PA; Lus G; Avolio C; Gallo A; Vianello M; Onofrj M; Filippi M; Trojano M; Patti F
    Neurotherapeutics; 2021 Apr; 18(2):905-919. PubMed ID: 33528815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
    Zhornitsky S; Greenfield J; Koch MW; Patten SB; Harris C; Wall W; Alikhani K; Burton J; Busche K; Costello F; Davenport JW; Jarvis SE; Lavarato D; Parpal H; Patry DG; Yeung M; Metz LM
    PLoS One; 2015; 10(4):e0123824. PubMed ID: 25867095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence.
    Ferraro D; Camera V; Baldi E; Vacchiano V; Curti E; Guareschi A; Malagù S; Montepietra S; Strumia S; Santangelo M; Caniatti L; Foschi M; Lugaresi A; Granella F; Pesci I; Motti L; Neri W; Immovilli P; Montanari E; Vitetta F; Simone AM; Sola P
    Curr Med Res Opin; 2018 Oct; 34(10):1803-1807. PubMed ID: 29526118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
    Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
    Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
    Juto A; Fink K; Al Nimer F; Piehl F
    Mult Scler Relat Disord; 2020 Jan; 37():101468. PubMed ID: 31683231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data.
    Engmann NJ; Sheinson D; Bawa K; Ng CD; Pardo G
    J Manag Care Spec Pharm; 2021 May; 27(5):639-649. PubMed ID: 33624535
    [No Abstract]   [Full Text] [Related]  

  • 9. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world persistence of multiple sclerosis disease-modifying therapies.
    Tallantyre EC; Dobson R; Froud JLJ; St John FA; Anderson VM; Arun T; Buckley L; Evangelou N; Ford HL; Galea I; George S; Gray OM; Hibbert AM; Hu M; Hughes SE; Ingram G; Kalra S; Lim CE; Mathews JTM; McDonnell GV; Mescall N; Norris S; Ramsay SJ; Rice CM; Russell MJ; Shawe-Taylor MJ; Williams TE; Harding KE; Robertson NP
    Eur J Neurol; 2024 Jul; 31(7):e16289. PubMed ID: 38567516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy.
    Marangi A; Farina G; Vicenzi V; Forlivesi S; Calabria F; Marchioretto F; Forgione A; Rossi F; Stenta G; Vianello M; Gajofatto A; Benedetti MD
    Mult Scler Relat Disord; 2020 Jun; 41():102004. PubMed ID: 32078935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cross-sectional analysis of persistence to disease-modifying therapies in treatment naïve and experienced patients with relapsing multiple sclerosis at a health-system specialty pharmacy.
    Kozlicki MZ; Markley B; Shah NB; DeClercq J; Choi L; Zuckerman AD
    Mult Scler Relat Disord; 2022 Jul; 63():103860. PubMed ID: 35609353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry.
    Stuchiner T; Lucas L; Baraban E; Spinelli KJ; Chen C; Smith A; Hashemi L; Cohan S
    BMC Neurol; 2020 Dec; 20(1):439. PubMed ID: 33272224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.
    Kister I; Spelman T; Alroughani R; Lechner-Scott J; Duquette P; Grand'Maison F; Slee M; Lugaresi A; Barnett M; Grammond P; Iuliano G; Hupperts R; Pucci E; Trojano M; Butzkueven H;
    J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1133-7. PubMed ID: 27298148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
    Warrender-Sparkes M; Spelman T; Izquierdo G; Trojano M; Lugaresi A; Grand'Maison F; Havrdova E; Horakova D; Boz C; Oreja-Guevara C; Alroughani R; Iuliano G; Duquette P; Girard M; Terzi M; Hupperts R; Grammond P; Petersen T; Fernandez-Bolaños R; Fiol M; Pucci E; Lechner-Scott J; Verheul F; Cristiano E; Van Pesch V; Petkovska-Boskova T; Moore F; Kister I; Bergamaschi R; Saladino ML; Slee M; Barnett M; Amato MP; Shaw C; Shuey N; Young C; Gray O; Kappos L; Butzkueven H; Kalincik T; Jokubaitis V;
    Mult Scler; 2016 Apr; 22(4):520-32. PubMed ID: 26199347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60.
    Hua LH; Fan TH; Conway D; Thompson N; Kinzy TG
    Mult Scler; 2019 Apr; 25(5):699-708. PubMed ID: 29557704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
    Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors.
    Bsteh G; Feige J; Ehling R; Auer M; Hegen H; Di Pauli F; Deisenhammer F; Reindl M; Berger T
    Mult Scler; 2017 Aug; 23(9):1241-1248. PubMed ID: 27765877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
    Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
    Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.